Structure Therapeutics Inc. Sponsored ADR (NASDAQ:GPCR) Stock Has Consensus Price Target of $110.91 According to Brokerages

Key Points

• Structure Therapeutics has a “Moderate Buy” consensus rating from 16 analysts, with 12 buys, two strong buys, one hold and one sell. The average 12-month price target is $110.91.
• Shares opened at $22.88, compared with a 52-week range of $20.73 to $94.90; the stock has a market capitalization of approximately $1.59 billion.
• The company reported a quarterly loss of $0.49 per share, missing the $0.39 consensus estimate, while institutional investors own 91.78% of outstanding shares.

Structure Therapeutics Inc. Sponsored ADR (NASDAQ:GPCR - Get Free Report) has earned a consensus rating of "Moderate Buy" from the sixteen ratings firms that are presently covering the stock, Marketbeat reports. One investment analyst has rated the stock with a sell rating, one has given a hold rating, twelve have issued a buy rating and two have issued a strong buy rating on the company. The average 1 year target price among analysts that have issued ratings on the stock in the last year is $110.91.

Several research firms have commented on GPCR. Weiss Ratings upgraded Structure Therapeutics from a "sell (e+)" rating to a "sell (d-)" rating in a research note on Tuesday, October 6th. Citizens Jmp reiterated a "market outperform" rating and issued a $110.00 price objective on shares of Structure Therapeutics in a report on Wednesday, September 9th. Citigroup reiterated a "market outperform" rating on shares of Structure Therapeutics in a report on Friday, August 7th. Canaccord Genuity Group set a $111.00 price objective on shares of Structure Therapeutics in a research report on Friday, August 7th. Finally, Wall Street Zen cut shares of Structure Therapeutics from a "sell" rating to a "strong sell" rating in a report on Saturday, October 3rd.

Structure Therapeutics Price Performance

Shares of Structure Therapeutics stock opened at $22.88 on Wednesday. The firm has a market cap of $1.59 billion, a price-to-earnings ratio of -22.88 and a beta of -1.30. The stock's 50-day moving average is $38.42 and its 200-day moving average is $43.62. Structure Therapeutics has a one year low of $20.73 and a one year high of $94.90.

Structure Therapeutics (NASDAQ:GPCR - Get Free Report) last posted its quarterly earnings data on Thursday, August 6th. The company reported ($0.49) earnings per share for the quarter, missing the consensus estimate of ($0.39) by ($0.10). On average, equities analysts expect that Structure Therapeutics will post -1.87 EPS for the current year.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently modified their holdings of the company. Squarepoint Ops LLC raised its stake in Structure Therapeutics by 454.5% in the second quarter. Squarepoint Ops LLC now owns 125,575 shares of the company's stock valued at $6,740,000 after buying an additional 102,929 shares during the period. Wellington Management Group LLP boosted its holdings in shares of Structure Therapeutics by 1.6% during the 2nd quarter. Wellington Management Group LLP now owns 7,379,433 shares of the company's stock worth $396,054,000 after buying an additional 119,146 shares during the period. Orbimed Advisors LLC boosted its holdings in shares of Structure Therapeutics by 27.0% during the 1st quarter. Orbimed Advisors LLC now owns 1,475,403 shares of the company's stock worth $71,114,000 after buying an additional 313,600 shares during the period. Handelsbanken Fonder AB acquired a new position in Structure Therapeutics in the 2nd quarter valued at about $1,041,000. Finally, SEB Asset Management AB acquired a new position in Structure Therapeutics in the 1st quarter valued at about $11,811,000. Institutional investors own 91.78% of the company's stock.

About Structure Therapeutics

Structure Therapeutics NASDAQ: GPCR is a clinical-stage biopharmaceutical company developing oral small-molecule medicines for chronic metabolic diseases. The company uses structure-based drug discovery and focuses on G protein-coupled receptors (GPCRs), a broad class of drug targets involved in metabolic and cardiovascular processes.

Its lead product candidate is GSBR-1290, an investigational oral GLP-1 receptor agonist being developed for obesity and type 2 diabetes. Structure Therapeutics is also advancing additional discovery and preclinical programs intended to address metabolic and related chronic diseases.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.